| Click here for more Information and to Register |
 |
|
|
| Click here for more Information and to Register |
|
| Agenda |
6:00 - 6:05 Opening Remarks/Audience Pre-Test
6:05 - 6:25 ACNE – Clinical Update, New Tools
for Practice
Magdalene Dohil, MD
6:25 - 6:45 ACTINIC KERATOSIS – Clinical Update
with a Focus on Identification and
Treatment
Murad Alam, MD
6:45 - 7:20 CASE STUDIES – Audience Interactive
Bernard A. Cohen, MD, FAAP &
Neil Brooks, MD
- ACNE CASE: 4 week old healthy infant with
neonatal/infantile acne.
- AK CASE: 48-year-old male with Fitzpatrick skin
type II and solar damage
- ACNE CASE: Healthy teenage boy with skin of
color requiring acne therapy
- AK CASE: 56-year-old physically active woman
from Boulder, Colorado that uses no sun protection
7:20 - 7:25 Audience Post-Test
7:25 - 7:45 Panel Discussion with Audience Q&A |
|
| Faculty |
Bernard A. Cohen, MD, FAAP (Co-Chair)
Professor, Dermatology and Pediatrics
Johns Hopkins University School of Medicine
Director of Pediatric Dermatology
Johns Hopkins Children's Center
Baltimore, MD |
Neil Brooks , MD (Co-Chair)
Past President, AAFP
Medical Director
Vernon Manor Health Care Center
Vernon, CT |
|
|
Murad Alam, MD
Assistant Professor of Dermatology
and Otalaryngology
Chief of Cutaneous and Aesthetic Surgery
Northwestern University Feinberg School of Medicine
Chicago, IL |
Magdalene Dohil, MD
Assistant Clinical Professor of Pediatrics
and Medicine (Dermatology)
University of California, School of Medicine
Rady Children’s Hospital
San Diego, CA |
|
|
|
| Program Overview |
In the United States, both Acne and Actinic Keratosis are increasingly
prevalent skin disorders and important concerns for clinicians.
Acne is a disease that can be seen in the first year of life, early childhood,
prepubertal age, and puberty. Acne is a polymorphic disease
with noninflammatory and inflammatory aspects and a wide spectrum
of severity. The pattern of disease, relative severity, distribution, and
patient's social circumstances will influence appropriate management,
however, effective management also includes patient education about
acne, its natural history, and dispelling acne myths.
Since the 1960s, the incidence of nonmelanoma skin cancer
(NMSC) has been increasing 4% to 8% annually to the point that
NMSC now constitutes more than one-third of all US cancer cases.
Actinic keratosis (AK) is now considered the earliest clinically recognizable
manifestation of squamous cell carcinoma (SCC) of the skin,
one of the two main types of NMSC.
This program is designed to reinforce and supplement the clinician’s
knowledge about the pathogenesis, recognition, and management of
these two skin disorders. Emphasis will be placed on highlighting available
therapeutic options, and the integral role played in each component
of management to further ensure positive patient outcomes. |
|
| Learning Objectives |
The Johns Hopkins University School of Medicine takes responsibility for
the content, quality, and scientific integrity of this CME activity.
At the conclusion of this activity, participants should be able to:
- State the prevalence and pathogenesis of Acne and AK in
order to improve treatment outcomes
- Discuss the identification process, differential diagnoses and
currently used therapies for Acne and AK
- Utilizing clinical data, analyze the prognosis for the different
stages and the efficacy of treatment options of Acne and AK
- Evaluate various treatment methods, focusing on pharmacologic
agents that improve patient overall quality of life
|
|
| CME Information |
This activity has been reviewed and is acceptable for up to 3.50 Prescribed credits by the American Academy of Family Physicians. Of these credits, 1.75 conforms to the AAFP criteria for evidence-based CME clinical content. CME credit has been increased to reflect 2 for 1 credit for only the EB CME portion. When reporting CME credit, AAFP members should report total Prescribed credits earned for this activity. It is not necessary for members to label credit as evidence-based CME for reporting purposes.
The EB CME credit awarded for this activity was based on practice recommendations that were the most current with the strongest level of evidence available at the time this activity was approved. Since clinical research is ongoing, the American Academy of Family Physicians recommends that learners verify sources and review these and other recommendations prior to implementation into practice.
Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with
the extent of their participation in the activity.
Intended Audience
This activity is designed for Dermatologists. There are no prerequisites for attendees.
Americans with Disabilities Act
The Johns Hopkins University School of Medicine fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.
Full Disclosure Policy Affecting CME Activities
It is the policy of the Johns Hopkins University School of Medicine that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational
activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and
resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the course handout materials.
Supported by an educational grant from Dermik Laboratories, a subsidiary of sanofi-aventis U.S. |
|
|
